Markets
Leaderboard
Will Roche and Atea Pharmaceuticals' antiviral drug against Covid-19 be considered safe and effective by the end of 2021? No: real money 72%, play money 37% Yes: real money 28%, play money 63% Volume: real money 148.43614162, play money 5500 Bettors: real money 2, play money 3 Categories: Science, Transmissible Diseases, Covid-19 (Coronavirus), Treatments Related markets Nipah virus declared a public health emergency by the WHO in 2026? (ID: 233776) Volume: real 100.18015496, play 14933.4347 Bettors: real 4, play 3 Leading (real money): Nipah virus declared a public health emergency by the WHO in 2026? 11% Leading (play money): Nipah virus declared a public health emergency by the WHO in 2026? 6% Antarctic sea ice minimum to decrease in 2027? (ID: 235045) Volume: real 500.10026694, play 50000 Bettors: real 4, play 0 Leading (real money): Antarctic sea ice minimum to decrease in 2027? 81% Leading (play money): Antarctic sea ice minimum to decrease in 2027? 81%

Will Roche and Atea Pharmaceuticals' antiviral drug against Covid-19 be considered safe and effective by the end of 2021?

Market Rules

Researchers at Roche and Atea Pharmaceuticals have tried to develop an antiviral drug to treat covid-19 since the beginning of the pandemic. These kinds of drugs aim to disrupt the virus's ability to replicate in the human body.

The treatment itself will likely be based on oral intake of daily pills after diagnosis, similar to how hepatitis C, herpes, and influenza antivirals are used. If the results of the studies are positive, it's possible that the drug is approved for use before the end of 2021.

If the results from phase III trials of Roche and Atea Pharmaceuticals' antiviral drug against Covid-19 are released by December 31, 2021, and the international scientific community considers that they prove the drug is indeed safe and effective against COVID-19, this market will be resolved as "Yes". Alternatively, this market may also be resolved as "Yes" if the drug is approved by at least one of the following agencies before that: ANVISA (Brazil), FDA (USA or EMA (European Union).

This market will be resolved based on news (with verifiable sources) and scientific studies on the subject from sources or publications that Futuur finds credible and reputable, such as, but not restricted to, World Health Organization, Nature Magazine, Science and other specialized scientific journals.

Related Markets